Articles from CCS

CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, will present four peer-reviewed posters at the American Diabetes Association’s (ADA) 85th Scientific Sessions, which will take place June 20–23 in Chicago. These latest poster presentations illustrate CCS’s focus on delivering evidence-based approaches to diabetes care management that ensure patients have the education and coaching they need to thrive and cost-effectively stay adherent while managing their chronic condition.

CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced new data-driven findings that show the company’s proprietary AI-enabled predictive analytics and intervention platform — PropheSee™ — effectively identified approximately 28 percent of 55,000 Medicare fee-for-service (FFS) patients at risk of lapsing on continuous glucose monitoring (CGM) therapy. As a result of applying CCS’s predictive analytics and intervention platform to this high-risk Medicare population, more than $10 million in taxpayer dollars have already been saved.

CCS, a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions, announced the publication of new research in Clinical Diabetes, a peer-reviewed journal of the American Diabetes Association. The study, “Impact of Continuous Glucose Monitoring Sourcing on Real-World Adherence and Healthcare Costs: A Comparative Analysis by Insurance Type,” reveals significant advantages for patients receiving continuous glucose monitors (CGM) through durable medical equipment (DME) providers compared to pharmacy channels. This groundbreaking research demonstrates that efforts to expand access to CGMs by adding the pharmacy as a new channel for distribution — alongside the established DME provider channel — may be having the opposite intended impact, resulting in lower adherence and higher total costs of care.

CCS — a leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced a new report that looks at the strain felt by America’s primary care physicians (PCPs) and endocrinologists caring for the growing population of people with diabetes. In collaboration with independent market research firm PureSpectrum, CCS surveyed more than 100 PCPs and more than 100 endocrinologists in the U.S. Findings from the report demonstrate that many providers are not in a position to properly support the ongoing education and coaching needs of people living with diabetes. Also, the report reveals that health plans and their pharmacy benefit managers (PBMs) are urging some clinicians to steer patients away from durable medical equipment (DME) companies that traditionally provide patients with more comprehensive access to chronic care education and coaching.

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced new peer-reviewed research showing patients living with diabetes who use a continuous glucose monitoring (CGM) device stay on therapy longer and have a lower total cost of care when they receive their supplies through a medical benefit, instead of a pharmacy benefit. The peer-reviewed publication in the Journal of Medical Internet Research Diabetes (JMIR) used a retrospective claims analysis to demonstrate that patients receiving their CGM through the medical benefit instead of a pharmacy had 35% lower average annual total costs of care and 23% higher device adherence rates. CCS also recently presented supporting research at the ADCES and ISPOR conferences.

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced a new report revealing 57% of individuals living with diabetes in the United States think GLP-1 weight loss drugs alone may be a silver bullet for helping achieve their health goals. CCS, in collaboration with independent market research firm PureSpectrum, surveyed more than 1,500 individuals living with diabetes to understand their attitude as it relates to an array of timely issues, including growing demand for GLP-1 weight loss drugs and whether people living with type 2 diabetes feel like their provider relationship is setting them up for success when it comes to self-management of their chronic disease.

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced PropheSee™ a new, AI-powered predictive model for healthcare organizations focused on improving adherence in the population of people that have been prescribed a continuous glucose monitoring (CGM) device to help manage their diabetes. In addition to improved clinical outcomes, health plans and risk-bearing providers can also realize savings of up to $2,200 per patient per year from this increase in CGM adherence and better glycemic control.

CCS — leading provider of clinical solutions and home-delivered medical supplies for those living with chronic conditions — today announced the launch of its Scientific Advisory Council, which includes four industry leaders who will support CCS in its commitment to redefining patient care at home through a more holistic approach: Alexander Ding, MD, MBA; Karmeen Kulkarni, MS, RD, CD, CDCES, BC-ADM; Steven Wittlin, MD; and Francine Kaufman, MD. This news comes on the heels of the company’s recent announcement that Arti Masturzo, MD, joined CCS as its first-ever Chief Medical Officer.